
Novo Nordisk has successfully priced EUR 1.3bn (USD 1.6bn) notes, according to a press release published on Thursday.
The notes are issued in two tranches on June 4 2021. The first tranche, with an EUR 650m aggregate principal amount, matures on June 4 2024 with a coupon of 0 percent. The second tranche will have the same aggregate principal amount, matures on June 4 2028 and has a 0.125 percent coupon.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app